Smith Jeffrey T L — SEC Form 4 Insider Trading Activity
Summary
Updated Jul 16, 2026
Smith Jeffrey T L is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market sales: $476K.
Profile
Jeffrey T Smith L is the Executive Vice President and Chief Medical Officer of Zymeworks Inc. as of the SEC filing dated January 6, 2026. In this role, he leads medical strategy and clinical development for Zymeworks’ pipeline, including the clinical candidate zanidatamab, and oversees global clinical programs and regulatory interactions.
Jeffrey T Smith L is the Executive Vice President and Chief Medical Officer of Zymeworks Inc. as of the SEC filing dated January 6, 2026. In this role, he leads medical strategy and clinical development for Zymeworks’ pipeline, including the clinical candidate zanidatamab, and oversees global clinical programs and regulatory interactions.…
Has Smith Jeffrey T L been buying or selling stock?
Recorded transactions: 0 open-market purchases () and 2 open-market sales ($476K) across all tracked filings.
Where can I see all of Smith Jeffrey T L's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
